Insights into familial middle-age dementia suggest new avenues for treatment

February 23, 2018

Researchers centered at Tokyo Medical and Dental University(TMDU) identify novel therapeutic targets for the treatment of a hereditary form of frontotemporal lobar degeneration

Tokyo - Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset dementia, and can lead to personality changes, impaired speaking, and motor dysfunction. While most cases occur sporadically, several inherited forms of FTLD have been linked to genetic mutations, which can offer clues to the cause of the disease and potential approaches to treatment. In a study published in Nature Communications, researchers have now uncovered several key events that occur in a common form of familial FTLD linked to mutations in the PGRN gene.

FTLD is a neurodegenerative disease caused in part by the build-up of protein aggregates in neurons. Different forms of FTLD--including the two major hereditary forms of the disease, FTLD-tau and FTLD-TDP--are associated with the build-up of different proteins. The hallmark of FTLD-tau is accumulated tau protein, a well-known player in neurological disorders such as Alzheimer's disease. The hallmark of FTLD-TDP (the form linked to defective PGRN) is the accumulation of TDP43, whose role in the disease is poorly understood.

"One of the reasons less is known about FTLD-TDP is that the current disease models in mice look don't precisely mimic the way PGRN is mutated in patients," lead author Kyota Fujita of Tokyo Medical and Dental University(TMDU) explains. "We developed a new model by introducing a mutation in PGRN gene associated with FTLD-TDP. In contrast to the earlier models, the mice in our study exhibit behavioral and cognitive symptoms that very closely mirror the disease pathology seen in humans."

Using this model, the researchers set out to understand what differentiates PGRN-mutant mice from their healthy counterparts. They focused their search on phosphorylation, a process that is normally involved in cell signaling but is often implicated in neurodegenerative diseases. Phosphorylated proteins have an additional chemical charge that can alter their behavior. In patients with FTLD-tau, as well as in Alzheimer's disease, phosphorylation of tau is thought drive its accumulation in neurons.

The research team performed a comprehensive search for proteins that are phosphorylated when PGRN is mutated. Notably, they discovered that tau is phosphorylated and specifically localized to synapse in the mutant mice. This was a surprising find, given that tau does not accumulate and have not been implicated in the TDP form of the disease (FTLD-TDP). Nevertheless, they found that phosphorylated tau causes synapse loss, and may disrupt communication between neurons. The toxic tau was seen as early as 4 weeks in mice, while TDP43 did not appear until 24 weeks--suggesting that tau may play a more important role early in the disease.

"Our study shows that tau phosphorylation (but not tau aggregation) is central to the pathology of both forms of FTLD as well as of Alzheimer's disease," corresponding author Hitoshi Okazawa concludes. "In the case of FTLD-TDP, phosphorylated tau appears to drive early synapse changes long before TDP43 protein aggregates appear. The therapeutic implications of the study are clear, as the findings suggest that targeting tau phosphorylation may be an effective way to treat the disease at its earliest stages."

Over the course of the study, the team uncovered a number of molecular events that cause mutated PGRN to lead to tau phosphorylation. With many of the key signaling players now identified, the team is hopeful that future efforts can focus on possible treatment strategies for this form of the disease.

"The tau pathway looks to be a very promising treatment target for familial FTLD associated with PGRN mutations," Okazawa adds. "We're very excited to see how our findings will eventually translate into clinical improvement for these patients."

Tokyo Medical and Dental University

Related Phosphorylation Articles from Brightsurf:

University of South Carolina research finds trigger that leads to faster nerve healing
Damaged nerves regenerate faster when protein clusters are broken apart, releasing mRNAs that can be used to rebuild the nerve.

Potential drug treatment for particular type of lung-cancer
Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

New protein complex gets chromosomes sorted
Researchers from the University of Tsukuba have identified a novel protein complex that regulates Aurora B localization to ensure that chromosomes are correctly separated during cell division.

How cells decide the way they want to recycle their content
Researchers from Tokyo Medical and Dental University (TMDU) identified a new phosphorylation site of Ulk1 as a novel regulating mechanism of alternative autophagy.

Marker reveals if benign-appearing meningiomas are perilous
A modified protein in benign-appearing meningiomas can reveal which are truly benign and which are more dangerous and require more aggressive treatment, researchers have discovered.

Cell signalling breakthrough opens up new avenues for research
Researchers at the University of Liverpool have shown that the phenomenon of protein modification (phosphorylation) in cell signalling is far more diverse and complex than previously thought.

Chronobiology: Sleep and synaptic rhythms
Chronobiologists at Ludwig-Maximilians-Universitaet (LMU) in Munich, Germany, show in two articles in the journal Science how critical the sleep-wake cycle is for protein and phosphorylation dynamics in synapses to ultimately regulate its activity.

Scientists find precise control of terminal division during plant stomatal development
A research group led by Prof. LE Jie at the Institute of Botany of the Chinese Academy of Sciences found a genetic suppressor of flp stomatal defects.

Phosphorylation of Regnase-1 lets IL-17 run amok
A research team led by Osaka University found that the cytokine interleukin (IL)-17 triggers the phosphorylation of mRNA-degrading enzyme Regnase-1, resulting in excessive inflammation.

Inhibition of protein phosphorylation promotes optic nerve regeneration after injury
Research results from a recent study led by a Waseda University-led team suggest that the inhibition of phosphorylation of microtubule-binding protein CRMP2 could be a novel approach to the development of treatments for optic neuropathies, such as glaucoma and traumatic injury.

Read More: Phosphorylation News and Phosphorylation Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to